Pulmonx (LUNG) Cash & Equivalents (2019 - 2025)

Pulmonx (LUNG) has 7 years of Cash & Equivalents data on file, last reported at $69.8 million in Q4 2025.

• On a quarterly basis, Cash & Equivalents fell 1.63% year-over-year to $69.8 million in Q4 2025; TTM through Dec 2025 was $69.8 million, a 1.63% decrease from a year earlier, with the FY2025 full-year figure at $69.8 million, down 1.63% from the prior year.
• Cash & Equivalents for Q4 2025 stood at $69.8 million, down from $76.5 million in the prior quarter.
• Over the last five years, Cash & Equivalents for LUNG reached as high as $209.3 million in Q1 2021 and fell as low as $63.3 million in Q3 2024.
• Historically, Cash & Equivalents has averaged $108.2 million across 5 years, with a median of $98.3 million in 2023.
• Across the five-year window, Cash & Equivalents surged 1188.61% in 2021 and slumped 40.24% in 2022, its largest moves.
• Year by year, Cash & Equivalents stood at $148.5 million in 2021, then slumped by 31.48% to $101.7 million in 2022, then fell by 17.88% to $83.5 million in 2023, then decreased by 15.13% to $70.9 million in 2024, then slipped by 1.63% to $69.8 million in 2025.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $69.8 million in Q4 2025, $76.5 million in Q3 2025, and $75.5 million in Q2 2025.